The Event

In keeping with Oxford Global’s highly successful life sciences series, an expert panel of 40 speakers will present a full conference programme covering the topics outlined below. These topics have been compiled as a result of a comprehensive research process undertaken with an expert advisory board with members including Executive Directors and Professors from global pharmaceutical organisations and leading research institutions.

Stream Titles

  • Protein Purification & Downstream Processing
  • Antibody Discovery & Engineering
  • Protein Expression & Characterisation
  • Therapeutic Applications of Antibodies

Day 1 Stream 1 – Protein Purification & Downstream Processing

  • Overcoming purification challenges: mAbs and non-mAbs
  • High throughput techniques to accelerate downstream processing research
  • Optimising protein purification: integrated/continuous processing
  • High-throughput process development & scale-up considerations

Day 1 Stream 2 – Antibody Discovery & Engineering

  • Novel strategies for antibody engineering: Fc engineering and antibody-drug conjugates
  • Antibody library design: achieving flexibility and diversity
  • Technologies to enabling antibody lead selection with optimal developability
  • New antibody discovery platforms

Day 2 Stream 1 – Protein Expression & Characterisation

  • Streamlining protein production
  • Biophysical characterisation: higher order structure and conformation
  • Characterisation of antibody drug conjugates and new biotherapeutics
  • Novel technologies: glycosylation, protein labelling, HDX mass spectrometry
  • Engineering CHO cells for optimised protein expression
  • Glycan structure-function characterisation and molecule optimisation

Day 2 Stream 2 – Therapeutic Applications of Antibodies

  • Antibodies to target ion channels
  • Immuno-oncology: insights into the next wave of antibody therapies
  • Overcoming the clinical challenges associated with therapeutic antibodies
  • Novel bispecific antibodies and their therapeutic potential
Agilent copy.jpgSanger.jpgGlenbervie.jpgAIMM.jpgNovozymes.jpgIBIS.jpgMetanomics.jpgChelatec.jpgShire.jpgMRC.jpgPfizer 2.jpgSGS.jpgAffibody.jpg